Biofrontera Inc. - Common Stock (BFRI)
Frequently Asked Questions About Biofrontera Inc. - Common Stock (BFRI)
How can investors get updates on Biofrontera's performance?
Investors can stay updated on Biofrontera Inc.'s performance by regularly checking corporate announcements, press releases, and financial reports published on its official website. The company also engages in quarterly earnings calls and investor presentations to provide valuable insights into its business developments and strategic direction.
How does Biofrontera approach regulatory challenges?
Biofrontera Inc. approaches regulatory challenges by closely collaborating with expert regulatory affairs teams and staying informed about global health regulations. The company prioritizes compliance and is prepared to adapt its strategies to meet the requirements of various regulatory bodies, thereby ensuring timely approval and market access for its products.
How does Biofrontera collaborate with healthcare providers?
Biofrontera Inc. collaborates with healthcare providers through educational initiatives, clinical trials, and strategic partnerships. The company provides resources, training, and support to dermatologists in utilizing its products, ensuring that they are well-informed about the latest treatment options available for their patients.
How does Biofrontera ensure product safety and efficacy?
Biofrontera Inc. ensures product safety and efficacy through rigorous clinical trials, adhering to regulatory standards set forth by agencies such as the FDA. The company follows extensive protocols to monitor patient outcomes and gather data, enabling it to continually optimize its products based on real-world feedback and clinical evidence.
Is Biofrontera Inc. publicly traded?
Yes, Biofrontera Inc. is publicly traded on the Nasdaq under the ticker symbol BFRI. Being a publicly traded company allows Biofrontera to raise capital for its continued development and commercialization efforts, as well as to provide transparency to its investors.
What are Biofrontera's goals for future product development?
Biofrontera Inc. aims to continually expand its portfolio of dermatological products by investing in research and development to address unmet medical needs. The company is focused on introducing new therapies to the market, enhancing existing products, and exploring additional indications for their current technologies to provide patients with comprehensive skin treatment options.
What are the financial performance indicators for Biofrontera?
Biofrontera Inc.'s financial performance indicators include revenue growth from product sales, research and development expenses, and operational efficiency metrics. The company regularly communicates its financial results to shareholders, providing insights into its profitability, market position, and future projections, which are essential for maintaining investor confidence.
What are the key products offered by Biofrontera Inc.?
Biofrontera Inc. offers a range of dermatological products, including photodynamic therapy options like Ameluz, a prescription medication used to treat actinic keratosis, and the BF-RhodoLED system, which complements the treatment by enhancing its effectiveness. These products reflect Biofrontera's commitment to treating skin conditions with advanced methodologies.
What does Biofrontera Inc. do?
Biofrontera Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs to treat skin conditions. The company specializes in dermatology, particularly in addressing skin cancer and other skin diseases. Its primary products are specialized formulations that utilize proprietary technologies aimed at improving skin health and therapeutic outcomes.
What is Ameluz?
Ameluz is a topical gel product developed by Biofrontera Inc. It is used specifically for the treatment of actinic keratosis, a precancerous condition caused by prolonged sun exposure. Ameluz utilizes photodynamic therapy, where the gel is applied to the affected skin and activated using a specific light source, effectively targeting and destroying abnormal cells.
What is Biofrontera's commitment to sustainability?
Biofrontera Inc. is committed to sustainability through various initiatives aimed at minimizing its environmental footprint while producing effective dermatological products. The company emphasizes responsible sourcing, efficient manufacturing processes, and sustainable business practices that align with broader environmental goals.
What is the market strategy of Biofrontera Inc.?
Biofrontera Inc.'s market strategy focuses on expanding its footprint in the dermatology market through innovative products and efficient distribution channels. The company aims to educate healthcare professionals about its treatments while establishing partnerships with various clinics and dermatology practices to enhance product accessibility and patient outcomes.
What is the significance of photodynamic therapy in Biofrontera's products?
Photodynamic therapy (PDT) plays a crucial role in Biofrontera's treatment offerings. This minimally invasive therapy leverages light-sensitive drugs and specific light wavelengths to effectively destroy abnormal cells. Biofrontera's innovative approaches in PDT help in treating skin diseases with improved efficacy and reduced patient recovery time.
What is the significance of the BF-RhodoLED system?
The BF-RhodoLED system is vital in enhancing Biofrontera Inc.’s photodynamic therapy protocols. This specialized light-emitting device is designed specifically for use with Ameluz to activate the drug more effectively, ensuring optimal treatment delivery for actinic keratosis and improving patient outcomes in clinical settings.
What kind of research does Biofrontera conduct?
Biofrontera Inc. engages in both preclinical and clinical research to develop new dermatological products and improve existing therapies. This research focuses on innovative treatment methods, exploring new formulations, and conducting trials to validate the effectiveness and safety of its drug candidates in addressing skin conditions.
When was Biofrontera Inc. founded?
Biofrontera Inc. was founded in 2001. Since its inception, the company has focused on research and development in the field of dermatology and has expanded its operations to include clinical development, regulatory affairs, and commercialization of its innovative products.
Where does Biofrontera operate internationally?
Biofrontera Inc. operates not only in the United States but also has a presence in several international markets, primarily in Europe. The company seeks to leverage global demand for its dermatology products, engaging in regulatory submissions and partnerships to facilitate product availability in multiple countries.
Where is Biofrontera Inc. headquartered?
Biofrontera Inc. is headquartered in Boston, Massachusetts. The company has established its presence in the United States as part of its strategy to expand its market reach and provide access to its innovative dermatological products and treatments to patients.
Who are Biofrontera's competitors?
Biofrontera Inc. competes with several companies in the dermatology sector, including larger pharmaceutical firms as well as specialized biotech companies. Competitors may offer various skin treatment options, including traditional pharmaceuticals and innovative emerging therapies, creating a dynamic and competitive landscape.
What is the current price of Biofrontera Inc. - Common Stock?
The current price of Biofrontera Inc. - Common Stock is 1.100
When was Biofrontera Inc. - Common Stock last traded?
The last trade of Biofrontera Inc. - Common Stock was at 4:00 pm EDT on April 29th, 2026